Nanostics Validates AI-Driven Prostate Cancer Prediction Models
Nanostics Inc. has announced the publication of a study validating its ClarityDX Prostate models, which use AI to predict aggressive prostate cancer. The study, published in npj Digital Medicine, demonstrates that these models can accurately assess cancer risk, potentially reducing unnecessary biopsies. The models incorporate patient clinical features and laboratory tests, with options to include MRI and digital rectal exam data. The research highlights the models' high accuracy and potential to improve clinical decision-making in prostate cancer screening. 
